Imidazoline receptor I2 subtype (I2 receptor)

The Imidazoline receptor I2 subtype is a pharmacologically defined receptor or group of binding sites characterized by high affinity for imidazoline compounds, particularly discriminated using ligands such as idazoxan and 2-BFI[2][3][4]. Unlike many well-defined receptor classes, the I2 receptor is heterogeneous, with at least four protein components identified as candidate binding sites but without a single cloned gene or protein structure[2][3]. Known binding sites include an allosteric site on mitochondrial monoamine oxidase and brain creatine kinase[1][2]. I2 receptors are widely expressed in the central nervous system, especially in brain regions involved in pain and mood regulation[5]. Agonists at the I2 receptor demonstrate potent analgesic effects for chronic and inflammatory pain and show potential for neuroprotection in preclinical models[2][3][5]. The I2 receptor is regarded as a promising therapeutic target for non-opioid analgesic drug development, exemplified by the ligand CR4056, which has progressed to phase II clinical trials[2][3]. However, the incomplete molecular characterization and heterogeneity of I2 receptor components pose challenges for both mechanistic understanding and drug development.

Other names

Imidazoline I2 receptorI2-IRI2 binding site

Allosteric modulation of mitochondrial monoamine oxidase (proposed primary mechanism for some binding sites) Analgesic action and neuroprotection via unknown or multiple mechanisms, potentially involving modulation of central monoamine neurotransmission and creatine kinase interaction Idazoxan acts as an antagonist by blocking ligand binding at I2 sites